

Experimental/Investigational Services

Policy ID:	HHO-DE-MP-1050
Approved By:	Highmark Health Options – Market Leadership
Provider Notice Date:	12/15/2021; 03/01/2023
Original Effective Date:	01/15/2022; 04/01/2023
Annual Approval Date:	11/24/2021; 10/26/2022
Last Revision Date:	12/27/2021; 10/26/2022
Products:	Medicaid
Application:	All participating hospitals and providers
Page Number(s):	1 of 1

Disclaimer

Highmark Health Options medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

Highmark Health Options may not provide coverage under medical surgical benefits of the Company's Medicaid products for experimental/investigational services.

Refer to Noncovered Services policy for more information.

DEFINITIONS

Highmark Health Options (HHO) – Managed care organization serving vulnerable populations that have complex needs and qualify for Medicaid. Highmark Health Options members include individuals and families with low income, expecting mothers, children, and people with disabilities. Members pay nothing to very little for their health coverage. Highmark Health Options currently services Delaware Medicaid: Delaware Healthy Children Program (DHCP) and Diamond State Health Plan Plus members.

Experimental/Investigational Services – A treatment, procedure, facility, equipment, drug, service, or supply (“intervention”) that has been determined not to be medically effective for the condition being treated.

POLICY UPDATE HISTORY

11/24/2021	Approved in medical policy committee
12/27/2021	Approved in QI/UM
10/26/2022	Annual review; approved in medical policy committee
11/2022	Approved in QI/UM